Miguel A Escobar
Overview
Explore the profile of Miguel A Escobar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Escobar M, Hoffman M, Castaman G, Hermans C, Mahlangu J, Oldenburg J, et al.
Res Pract Thromb Haemost
. 2025 Feb;
9(1):102670.
PMID: 39990097
Management of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa). Two rFVIIa products are commercially approved for use in the...
2.
Skinner M, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, et al.
Haemophilia
. 2024 Dec;
PMID: 39648854
Introduction: The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF-McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the...
3.
Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, et al.
Haemophilia
. 2024 Dec;
PMID: 39642092
Introduction: Evidence-based clinical practice guidelines drive optimal patient care and facilitate access to high-quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from...
4.
Poston J, Bryan C, von Drygalski A, Al Banaa K, Zhou J, Parnes A, et al.
Blood Adv
. 2024 Oct;
8(22):5896-5905.
PMID: 39361769
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST)....
5.
Roberts J, Escobar M, Acharya S, Hwang N, Wang M, Hale S, et al.
Haemophilia
. 2024 May;
30(4):970-980.
PMID: 38751022
Introduction: Gastrointestinal (GI) bleeding events (BEs) in von Willebrand disease (VWD) are difficult to diagnose and often recurrent. Limited data from clinical trials has led to lack of consensus on...
6.
Yohannan B, Montanez N, Escobar M
Cleve Clin J Med
. 2024 May;
91(5):308-317.
PMID: 38692703
No abstract available.
7.
Escobar M, Kavakli K
Haemophilia
. 2023 Oct;
30(1):59-67.
PMID: 37902395
Introduction: Hereditary factor X (FX) deficiency (HFXD) is an autosomal recessive rare bleeding disorder that leads to defects in the FX protein. Depending on the degree of deficiency, patients may...
8.
Tran D, Benson C, Boice J, Chitlur M, Dunn A, Escobar M, et al.
Expert Rev Hematol
. 2023 Mar;
16(sup1):19-37.
PMID: 36920859
Background: Decades of research have transformed hemophilia from severely limiting children's lives to a manageable disorder compatible with a full, active life, for many in high-income countries. The direction of...
9.
Hancock J, Escobar M
Expert Rev Hematol
. 2023 Mar;
16(3):157-161.
PMID: 36861346
Introduction: Von Willebrand Factor (VWF) containing concentrates have been used for the treatment of von Willebrand Disease (VWD) for many years. Recently, however, a novel recombinant VWF (rVWF or vonicog...
10.
Escobar M, Beijlevelt M, Loney A, Mahlangu J, Nanayakkara L, Neme D, et al.
Haemophilia
. 2022 Jul;
28(5):S129-S131.
PMID: 35811115
No abstract available.